Dyadic International (NASDAQ:DYAI) Shares Pass Below 50-Day Moving Average – Time to Sell?

Dyadic International, Inc. (NASDAQ:DYAI)’s stock price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.64 and traded as low as $1.37. Dyadic International shares last traded at $1.50, with a volume of 114,192 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Dyadic International in a research note on Thursday, November 14th.

Dyadic International Price Performance

The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15. The business’s 50-day moving average price is $1.63 and its two-hundred day moving average price is $1.41. The firm has a market cap of $43.79 million, a price-to-earnings ratio of -6.43 and a beta of 0.89.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DYAI. Two Sigma Securities LLC bought a new position in shares of Dyadic International during the fourth quarter worth about $25,000. Millennium Management LLC acquired a new stake in Dyadic International during the fourth quarter valued at approximately $28,000. Jane Street Group LLC acquired a new stake in Dyadic International during the fourth quarter valued at approximately $45,000. Bank of America Corp DE lifted its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the last quarter. Finally, Inlet Private Wealth LLC acquired a new position in shares of Dyadic International in the 4th quarter worth approximately $52,000. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.